MedTrace Logo

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

NCT01301157 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2015-11-05

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of M518101 and the dose relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients.

Conditions

Interventions

DRUG

M518101

Proper quantity twice a day

DRUG

placebo

Proper quantity twice a day

DRUG

Dovonex

Proper quantity twice a day

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301157 on ClinicalTrials.gov